Johnson & Johnson stock heads into the open after a modest gain

At the close on September 4, 2026, Johnson & Johnson stock finished near USD 160 on the NYSE with a small percent gain, as defensive healthcare names outperformed the broader market. Volume was moderate compared with recent sessions.

Johnson & Johnson stock closed at USD 160.29 on the NYSE on September 4, 2026, up 0.4% from the prior session according to market data.Yahoo Finance The stock traded between USD 159.22 and USD 160.86 that day, leaving the close near the upper end of the intraday range.Yahoo Finance Relative to its year-to-date advance of about 35% through the latest Friday close, the move represented a calm consolidation phase for a defensive healthcare heavyweight.247WallSt

September 4, 2026 in numbers

Johnson & Johnson Inc. (ISIN US4781601046, NYSE: JNJ) saw its shares move within a day range of USD 159.22 to USD 160.86 on September 4, 2026, before settling at USD 160.29.Yahoo Finance The percent gain of roughly 0.4% contrasted with a more muted performance in the broader large cap benchmarks, underlining the stock's defensive role during a volatile year for equities.247WallSt Trading volume on the last completed session was close to recent averages, indicating steady investor interest rather than a surge of speculative activity, while the price remained near the upper segment of its 52 week range highlighted in recent market commentary.247WallSt

Today’s drivers and upcoming catalysts

Today, Johnson & Johnson enters the new session without a scheduled earnings release, but recent discussions of oncology and immunology growth and rotation into healthcare remain in focus for investors as they interpret valuation and positioning signals.247WallSt Market participants also continue to track institutional trading disclosures around Johnson & Johnson, as several recent filings have detailed both stake increases and reductions, offering a window into how large holders are adjusting exposure to the stock in the current environment.MarketBeat Over the coming days, attention is likely to shift toward broader macroeconomic releases and sector peers in pharmaceuticals and consumer health, which can influence sentiment toward Johnson & Johnson by reshaping expectations for defensiveness and earnings resilience.